James McLaren

Managing Director

James is a managing director at TM Capital, one of Oaklins’ US member firms, and co-heads the firm's healthcare team. Based in New York, James also co-leads Oaklins’ medical devices team and has an extensive background in the healthcare industry. Recent transactions include two equity financings for CorVista Health, aggregating in excess of US$90 million, and multiple merger advisory transactions, including the sale of CPAP.Com, an internet supplier of products for the treatment of sleep apnea; the sale of Neoteryx, a producer of remote sampling devices for biological fluids; the sale of Ultimed, a producer of pen needles and syringes for insulin-dependent patients; the sale of VIP Petcare, a provider of veterinary services, to PetIQ, a NASDAQ-listed veterinary products company; and the sale of Sapheon, a manufacturer of products to treat venous insufficiency, to Covidien, a US public company subsequently purchased by Medtronic (NYSE – MDT).

James joined the firm from Asante Partners, which he founded more than 20 years ago to provide quality strategic advice to middle-market healthcare companies. Previously, he had a 20-year career advising corporate clients at Goldman Sachs, where he served as head of European corporate finance in London and of international corporate finance in New York, leading teams that executed significant global transactions. James has a BA in Economics (honors) from Oxford University. He is a member of the board of directors of ABK Biomedical, a developer of treatments for hypervascular tumors, and of CorVista Health, developing artificial intelligence-based products for the diagnosis of several cardiac diseases. James is also an advisory board member of Radius Ventures, a New York-based venture capital firm focused on the healthcare industry and serves on Oaklins’ executive committee as vice president of the organization in North America.